Key Takeaways
- The NOVOS Core double blind placebo controlled clinical study provides first-of-its-kind human evidence of simultaneous, positive effects on endothelial function, arterial flexibility, and healthy blood pressure already within the normal range from a single, multi-component nutritional intervention.
- Key markers of vascular aging were improved vs. placebo.
- The improvement observed in vascular function was equivalent to that associated with aerobic exercise in published studies.
- The results were uncommon, unusual for dietary supplement and nutrition research.
Today, NOVOS crossed a line that few longevity research programs ever reach.
After more than seven years of research, our flagship formulation, NOVOS Core, has now been evaluated end-to-end, from aging biology and mechanistic research, to animal aging models, to a randomized, double-blind, placebo-controlled human clinical trial (now entering peer review) measuring validated markers of human physiological function relevant to healthy aging.
That sentence alone represents something uncommon in the longevity supplement space. But the real story isn’t just that the study was human. It’s what was measured, how it was measured, and the magnitude and consistency of the results.
In reviewing the published human research in this field, it is rare to see consumer-accessible longevity formulations evaluated, let alone demonstrate effects of this magnitude, across multiple validated functional measures, all within the same randomized trial.
And what this study found sets a new bar for the field: NOVOS Core provides nutritional support for biological systems predictive of lifespan and healthspan.
Why This Study Is Different
Very few longevity supplements are ever clinically studied. Even fewer are placebo controlled, randomized, and run by top academic researchers. Among the few that are, most focus on proxy biomarkers: molecular signals such as NAD⁺ levels or inflammatory markers that can shift without necessarily indicating that an organ system is functioning differently. Those markers can be informative, but they don’t always tell us whether physiology itself has meaningfully changed.
From the beginning, our goal with NOVOS was different. We chose to evaluate organ-level physiological function, using endpoints that are widely accepted in medical and aging research but rarely used in supplement studies because they are difficult to measure, very difficult to improve in healthy populations, and require specialized clinical expertise.
Why Vascular Aging Was the First System We Studied
Vascular function was selected as the first system to evaluate in humans not because NOVOS was designed for cardiovascular biology alone, but because vascular aging is one of the earliest and most measurable reflections of aging biology itself.
Changes in endothelial responsiveness, arterial flexibility, and blood pressure often emerge decades before clinical disease and influence how organs function over time. If a longevity intervention can support vascular function earlier in life, it may help preserve resilience across multiple systems as aging progresses.
Vascular function strongly influences long-term organ health, resilience, and healthspan. Cardiovascular disease remains the #1 age-related cause of death globally and is responsible for roughly 1.5–2x more deaths annually than cancer, making vascular aging one of the most relevant systems to evaluate first when investigating interventions designed to support longevity.
In epidemiological research, vascular function metrics such as FMD, PWV, and systolic blood pressure are associated with long-term cardiovascular outcomes, and more broadly, with healthspan and lifespan, reinforcing why these endpoints are relevant in longevity research.
The Human Clinical Results
In healthy adults aged 40 and older, researchers observed statistically significant benefits over placebo across three independent markers of vascular aging, measured over six months.
The study found that NOVOS Core supports arterial flexibility, blood flow, and vessel structure in adult consumers of varying ages and health conditions, by targeting the root biology of vascular aging.
1) Endothelial Function (Flow-Mediated Dilation)
Endothelial function reflects how well blood vessels respond to changes in blood flow, a core aspect of vascular health.
In this trial, endothelial function improved acutely after the first dose and remained improved after six months of sustained use. The sustained improvement observed (~2.9 percentage points) was approximately 2–3x greater than what is typically reported for most studied nutritional interventions such as nitric oxide boosters (beetroot / dietary nitrates), cocoa flavanols, or tea polyphenols, and at the higher end of ranges reported for resistance training and aerobic exercise in published meta-analyses.
Just as importantly, the pattern of response matters. Seeing both early (at 2 hours) and durable (at 6 months, fasted, without NOVOS Core that day) improvements in endothelial function is uncommon in nutrition research that measures real physiological function rather than short-term signals.
2) Arterial Flexibility (Pulse Wave Velocity)
Arterial flexibility naturally decreases with age and is a well-established marker of vascular aging.
NOVOS Core improved arterial flexibility by approximately 1.18 m/s versus placebo at six months. In population studies, arterial flexibility typically decreases by about 1.0 m/s per decade of aging, which means the magnitude of the difference observed here represents a change distinct from typical age-related trajectories for vascular elasticity, based on published aging trajectories.
NOVOS Core’s improvement in PWV exceeded the effects reported for several of the better-performing supplements studied previously, including tea polyphenols, blueberries, CoQ10, folic acid, resveratrol, and omega-3 fatty acids, and was at the upper end of the range reported for resistance training, aerobic exercise, severe weight loss, and Mediterranean-style dietary interventions.
Effects of this magnitude are uncommon in randomized, placebo-controlled nutrition studies designed to measure organ-level function over months rather than hours or days.
3) Support for Healthy Blood Pressure Already Within the Normal Range
The study also observed statistically significant differences in systolic blood pressure between the intervention and placebo groups.
The placebo-adjusted difference in systolic blood pressure for NOVOS Core (~6.1 mmHg) exceeded the average reductions typically reported for many well-studied non-pharmacologic strategies in normotensive adults, including high-intensity interval training (HIIT), aerobic exercise programs, severe weight loss, DASH-style dietary patterns, nitric oxide–focused interventions such as beetroot or nitrate supplementation, omega-3, quercetin, and magnesium supplementation, which more commonly produce reductions in the ~2–4 mmHg range depending on baseline status. Importantly, participants entered the study with systolic blood pressure already within the normal range and remained within that range at follow-up, indicating support for healthy blood pressure without inducing hypotension.
Notably, these blood-pressure-related effects occurred without changes in lipid levels, highlighting that the observed benefits were driven by vascular and endothelial mechanisms rather than cholesterol modification.
Why Simultaneous Effects Matter
One of the most important and rare aspects of this study is that these benefits were observed simultaneously, across multiple independent vascular endpoints, in the same randomized trial.
In nutrition research, it is far more common to see modest movement in a single biomarker. Demonstrating consistent, statistically significant changes across endothelial function, arterial flexibility, and blood pressure support, all within the same population, is unusual and more often associated with intensive lifestyle interventions.
This convergence matters because vascular aging is not driven by a single pathway. It reflects interacting processes involving nitric oxide signaling, oxidative stress, mitochondrial function, inflammation, and cellular resilience. Measuring and improving multiple aspects of vascular function at once suggests that a multi-pathway strategy may be addressing upstream biology rather than isolated downstream effects.
Importantly, NOVOS Core was not designed as a cardiovascular supplement. It was uniquely developed and patents filed in 2020 around the 12 biological hallmarks of aging, a coordinated, multi-pathway approach intended to influence systemic aging biology. Cardiovascular function was selected as the first human test case because it is measurable, aging-sensitive, and directly tied to long-term healthspan and lifespan. Based on preclinical findings and early exploratory data in other domains, we are investigating whether NOVOS Core’s multi-system approach may influence additional organ systems across the body (we believe it does), and further studies are planned to prove this out.
The Broader Significance of This Study
Very few consumer-accessible longevity formulations are evaluated as complete systems, from mechanisms, to aging models, to validated human physiology. Even fewer are tested using endpoints typically reserved for cardiovascular and aging research.
“I see NOVOS as inspiring — they approach aging as a complex phenomenon, aiming at all pathways and hallmarks of aging simultaneously.”
– Dr. George Church, Genetics Professor, Harvard Medical School & MIT
“It’s the rigorously-researched, science-backed formulations that set NOVOS apart in the longevity supplements space.”
– Dr. Robert Lufkin MD, Professor, USC School of Medicine
“This trial provides rare human evidence that a multi-pathway nutritional strategy can meaningfully influence vascular aging biology itself. The magnitude and consistency of these effects across multiple vascular endpoints is unusual for a nutritional intervention in a healthy population.”
– Dr. Christian Heiss, MD, Professor of Cardiovascular Medicine at the University of Surrey and Senior Author of the NOVOS Core study
This trial was conducted by academic investigators using generally accepted clinical methods, registered in advance, and designed to measure functional outcomes over time rather than short-term signals. The academic authors retained control over the data and publication decisions, and the study followed rigorous standards uncommon in the supplement space.
Taken together, this body of work reflects a research philosophy we have held from the beginning: longevity deserves the same evidentiary standards we expect in other areas of health science.
Raising the Standard for Longevity Science
Healthy aging deserves a higher scientific standard.
After more than seven years of research, spanning mechanistic studies, animal aging models, and now a randomized, placebo-controlled human clinical trial measuring validated physiological function, NOVOS has achieved a level of evidence that is uncommon in this industry.
We believe this work sets a new benchmark for what longevity-focused nutritional interventions can demonstrate in humans not through marketing claims, but through measured, transparent, and reproducible science. And this is only the beginning.
You can view the preprint of the clinical study here.
Table of Flow Mediated Dilation Comparable Studies
| Intervention | Sustained FMD improvement (%) | Population Studied | Study Type | NOVOS Improvement Advantage | Full Key Reference | Fasted? |
| NOVOS Core | 2.9 | Healthy adults ≥40 years | Randomized, double-blind, placebo-controlled trial | Reference | Yes | |
| Blood orange juice (dietary polyphenols) | 2.39 | Healthy adults with overweight and obesity | Randomized, controlled, single-blind, crossover trial | 121% | https://pubmed.ncbi.nlm.nih.gov/32510144/ | Yes |
| Tea (green/black tea) | 2.3 | Healthy adults | Meta-analysis of controlled human intervention studies | 126% | https://pmc.ncbi.nlm.nih.gov/articles/PMC3048861/ | Yes |
| Dietary Polyphenols | 2.22 | Mixed/at-risk (cardiometabolic risks) | Meta-analysis of RCTs | 131% | https://pubmed.ncbi.nlm.nih.gov/36796437/ | |
| Resistance training | 2.11 | Adults/older adults healthy | Meta-analysis of RCTs | 137% | https://pubmed.ncbi.nlm.nih.gov/34399984/ | NR |
| Blueberries | 2.01 | Healthy adults (subgroup; pooled RCTs) | Systematic review + meta-analysis of RCTs | 144% | https://pubmed.ncbi.nlm.nih.gov/38887319/ | |
| CoQ10 | 1.69 | Healthy subjects with mild-to-moderate dyslipidemia | Randomized, double-blind, placebo-controlled trial | 172% | https://pubmed.ncbi.nlm.nih.gov/32326664/ | Yes |
| Curcumin supplementation | 1.64 | Mixed/at-risk (cardiometabolic risks) | Meta-analysis of RCTs | 177% | https://pubmed.ncbi.nlm.nih.gov/39265778/ | |
| Coenzyme Q10 | 1.63 | Mixed/at-risk (cardiometabolic risks) | Meta-analysis of RCTs | 178% | https://pubmed.ncbi.nlm.nih.gov/38630421/ | |
| Nitric oxide booster | 1.6 | Healthy adults | Systematic review + meta-analysis of RCTs | 181% | https://pubmed.ncbi.nlm.nih.gov/40679494/ | NR |
| Folic acid | 1.51 | Healthy adults (no-CVD) | Systematic review + meta-analysis of RCTs | 192% | https://pubmed.ncbi.nlm.nih.gov/36829207/ | NR |
| Resveratrol | 1.43 | Adults (mixed populations across RCTs; not healthy-only) | Systematic review + meta-analysis of RCTs | 203% | https://pubmed.ncbi.nlm.nih.gov/35833325/ | |
| Resveratrol | 1.38 | Obese but otherwise healthy adults | Randomized, double-blind, placebo-controlled trial | 210% | https://pubmed.ncbi.nlm.nih.gov/23743811/ | Yes |
| Mediterranean diet | 1.3 | Middle-aged and older adults | Systematic review and meta-analysis | 223% | https://pubmed.ncbi.nlm.nih.gov/28424187/ | Yes |
| Aerobic exercise | 1.2 | Healthy adults ( normotensive ) | Meta-analysis of RCTs | 242% | https://pubmed.ncbi.nlm.nih.gov/40197331/ | NR |
| Cocoa | 1.2 | Healthy, middle-aged adults (35–60 years) | Randomized, double-blind, placebo-controlled trial | 2.42x | https://pmc.ncbi.nlm.nih.gov/articles/PMC4594054/ | Yes |
| Flavonoids | 1.16 | Adults (mixed populations across RCTs; not healthy-only) | Meta-analysis of RCTs | 250% | https://pubmed.ncbi.nlm.nih.gov/22301923/ | NR |
| Severe weight loss | 1.11 | Overweight/obese adults | Meta-analysis | 261% | https://pubmed.ncbi.nlm.nih.gov/25568949/ | Yes |
| Walnuts | 1.04 | Adults across mixed cardiometabolic profiles | Systematic review and meta-analysis of randomized controlled trials | 279% | https://pubmed.ncbi.nlm.nih.gov/40972869/ | NR |
| Flavan-3-ols | 1 | Not-elevated BP (<120/<70) (healthy-like) | Meta-analysis of RCTs | 290% | https://pubmed.ncbi.nlm.nih.gov/40126033/ | NR |
| Omega-3 | 0.95 | Without CHD, but with CHD risk factors | Systematic review + meta-analysis of RCTs | 305% | https://pubmed.ncbi.nlm.nih.gov/37552456/ | Yes |
Table of Pulse Wave Velocity Comparable Studies
| Intervention | PWV Improvement (m/s) | Study Duration | Population Studied | Comparator | NOVOS Improvement Advantage | Study Reference | Fasted? |
| NOVOS Core | 1.18 | 6 months | Healthy adults ≥40 years | Placebo | Reference | Yes | |
| DASH dietary pattern | 1.07 | 2 weeks | Overweight/obese unmedicated stage 1 hypertensive adults | Control diet | 110% | https://pmc.ncbi.nlm.nih.gov/articles/PMC3306995/ | Yes |
| Magnesium | 1 | 24 weeks | Overweight/slightly obese adults (45–70y), mostly healthy | Placebo | 118% | https://pubmed.ncbi.nlm.nih.gov/27053384/ | Yes |
| Omega-3 | 0.93 | 12 weeks | Healthy older adults | Pre–post | 127% | https://pubmed.ncbi.nlm.nih.gov/26109192/ | Yes |
| Severe weight loss | 0.8 | 3–12 months | Overweight/obese adults | Mixed (mostly pre–post; some controls) | 148% | https://pubmed.ncbi.nlm.nih.gov/25414255/ | NR |
| HIIT | 0.62 | 8–24 weeks | Adults with CVD risk factors/ at high risk for CVD | Control | 190% | https://pubmed.ncbi.nlm.nih.gov/38694567/ | NR |
| Nitric oxide booster (beetroot / nitrate) | 0.59 | 4 weeks | Hypertensive adults (18–85y) | Placebo | 200% | https://pubmed.ncbi.nlm.nih.gov/25421976/ | Yes |
| Aerobic exercise | 0.58 | 11 weeks (range 4–52) | Healthy Adults | Control | 203% | https://pubmed.ncbi.nlm.nih.gov/38101857/ | NR |
| Aerobic exercise (MICT) | 0.41 | ≥4 weeks (median 12; range 4–52) | Healthy Adults | Usual care | 288% | https://pubmed.ncbi.nlm.nih.gov/25333969/ | NR |
| Cocoa flavanols | 0.4 | 4 weeks | Healthy middle-aged (men and women (35–60y)) | Placebo | 295% | https://pubmed.ncbi.nlm.nih.gov/26348767/ | Yes |
| Vitamin K2 | 0.34 | 1 year | Healthy subjects 40–70y | Placebo | 347% | https://pmc.ncbi.nlm.nih.gov/articles/PMC11901762/ | NR |
| Mediterranean diet | 0 | 1 year | Healthy older adults, 65–79 years | Habitual diet | No improvement | https://pubmed.ncbi.nlm.nih.gov/30636547/ | NR |
Table of Systolic Blood Pressure Comparable Studies
| Intervention | SBP reduction used for comparison (mmHg) | Reported SBP range (mmHg) | Population | NOVOS Improvement Advantage | Full study reference | Fasted? |
| NOVOS Core | -6.1 | −10.9 to −4.9 | Healthy adults ≥40 years | Reference | Heiss C. , et al. A randomized, double-blind, placebo-controlled trial of a multi-ingredient nutritional intervention on vascular function and blood pressure in healthy adults aged 40+. Manuscript under peer review, University of Surrey, 2024. | Yes |
| Soy nuts | −5.0 | SBP <120 mmHg | Normotensive subgroup | 122% | https://pubmed.ncbi.nlm.nih.gov/17533209/ | Yes |
| Cocoa | -4.4 | -0.9 to −7.9 | Normotensive subgroup | 139% | https://pubmed.ncbi.nlm.nih.gov/19910929/ | Yes |
| Nitric oxide booster (beetroot / nitrate) | -4.4 | -2.8 to -5.9 | Adults, majority healthy participants | 139% | https://pubmed.ncbi.nlm.nih.gov/23596162/ | NR |
| Flavonoids | -4.14 | -5.95 to -2.32 | Adults (mixed populations across RCTs; not healthy-only) | 147% | https://pubmed.ncbi.nlm.nih.gov/22301923/ | NR |
| Aerobic exercise | −4.04 | −5.32 to −2.75 | Normotensive subgroup | 151% | https://pubmed.ncbi.nlm.nih.gov/11926784/ | NR |
| HIIT | −3.92 | −6.1 to −1.7 | Normal blood pressure subgroup (healthy-like) | 156% | https://pubmed.ncbi.nlm.nih.gov/37491419/ | NR |
| DASH diet | -3.9 | -6.0 to -1.8 | Healthy adults subgroup | 156% | https://pubmed.ncbi.nlm.nih.gov/32330233/ | NR |
| Vitamin C | -3.11 | −4.52 to −1.71 | Non-hypertensive trials (subgroup) | 196% | https://pubmed.ncbi.nlm.nih.gov/22492364/ | NR |
| Resistance training | −2.86 | −4.6 to −1.1 | Normal blood pressure subgroup (healthy-like) | 213% | https://pubmed.ncbi.nlm.nih.gov/37491419/ | NR |
| Magnesium | −2.78 | −5.22 a −0.34 | General normotensive population | 219% | https://pubmed.ncbi.nlm.nih.gov/39519450/ | NR |
| Quercetin | −2.57 | −4.17 to −0.96 | Normotensive subgroup | 237% | https://pubmed.ncbi.nlm.nih.gov/35948195/ | NR |
| Dietary sodium reduction | −2.42 | −3.56 to −1.29 | Normotensive individuals (healthy-like subgroup) | 252% | https://pubmed.ncbi.nlm.nih.gov/23558162/ | NR |
| Severe weigth loss | -2.4 | Overweight nonhypertensive persons | 254% | https://pubmed.ncbi.nlm.nih.gov/1669517/ | NR | |
| Omega-3 | -2.38 | −3.62 a −1.13 | SBP <130 mmHg (healthy-like) | 256% | https://pubmed.ncbi.nlm.nih.gov/35647665/ | NR |
| Tea | -2.37 | -3.82 to -0.91 | Healthy adults subgroup | 257% | https://pubmed.ncbi.nlm.nih.gov/25137341/ | NR |
| Soy protein | -2.27 | −3.77 to −0.76 | Normotensive subgroup | 269% | https://pubmed.ncbi.nlm.nih.gov/21342608/ | NR |
| Endurance training | −2.1 | −3.3 to −0.83 | Prehypertensive adults | 290% | https://pubmed.ncbi.nlm.nih.gov/23525435/ | NR |
| Potassium | −2.1 | −3.81 a −0.38 | Normotensive/healthy-like | 290% | https://pubmed.ncbi.nlm.nih.gov/39519450/ | NR |
| Pistachios | −2.04 | −4.10 to 0.01 | Healthy adults (subgroup) | 299% | https://pubmed.ncbi.nlm.nih.gov/33198823/ | NR |
| Almonds | -1.76 | -2.36 to -1.17 | Healthy adults (subgroup) | 347% | https://pubmed.ncbi.nlm.nih.gov/32444059/ | NR |
| Curcumin | -1.67 | −2.30 to −1.04 | Healthy subjects (subgroup) | 365% | https://pubmed.ncbi.nlm.nih.gov/38220376/ | NR |
| Walnuts | −1.29 | −1.42 to −1.16 | Healthy subjects (subgroup) | 473% | https://pubmed.ncbi.nlm.nih.gov/32510725/ | NR |
| Mediterranean diet | -1.1 | −2.0 to −0.1 | Healthy older adults (>64y) | 555% | https://pubmed.ncbi.nlm.nih.gov/28424187/ | Yes |
| Flavan-3-ols | -0.5 | −6.6 to 5.5 | Not-elevated BP (<120/<70) (healthy-like) | 1,220% | https://pubmed.ncbi.nlm.nih.gov/40126033/ | NR |
| Coffee | 2.4 | 1.0 to 3.7 | Mostly normotensive participants | Worsening | https://pubmed.ncbi.nlm.nih.gov/10024321/ | NR |
